With buyout of MyoKardia, Bristol-Myers Squibb reaches into heart of Bay Area biotech

Like Bristol-Myers Squibb's acquisition of a small Redwood City biotech company 11 years ago transformed its cancer drug portfolio, the pharmaceutical giant expects its planned buyout of MyoKardia Inc. to accelerate its work on heart drugs. What it all means for the Bay Area, however, is undetermined at this point. This much is certain: Bristol-Myers Squibb (NYSE: BMY) bid $225 per share — or $13.1 billion — to buy Brisbane's MyoKardia Inc. (NASDAQ: MYOK) in a deal that could give the big drugmaker…

Click to view original post